Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.
What happened
FDA inspected the Kulim, Kedah, Malaysia facility from July 14 to 18, 2025. It found that laboratory records lacked complete raw data for microbiological release and stability testing before May 2025, and a company representative said logbooks were not available. FDA also found no growth promotion testing of microbiological media, no testing of a component for Burkholderia cepacia complex, and stability testing that did not test all active ingredients or impurities.
What FDA found
The firm did not keep complete original laboratory records, including raw data for microbiological release and stability tests.
21 CFR 211.194(a)The firm lacked sound laboratory controls: it did not test microbiological media for growth promotion before use and did not test a component for Burkholderia cepacia complex.
21 CFR 211.160(b)The firm lacked adequate stability data: it did not test each active ingredient at every planned timepoint and did not set impurity limits or test for impurities.
21 CFR 211.166(a)
What FDA wants
FDA tells the firm to respond in writing within 15 working days with corrective actions and supporting assessments, including data-integrity and stability remediation and independent laboratory review. If it cannot finish in that time, it must explain the delay and give a completion schedule.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- US companies that rely on Fulijaya as a drug manufacturer
- quality teams that use contract laboratories for microbial or stability testing
This is a summary. Read the original letter on fda.gov.